F EB RUARY 25, 2025 Agenda | Introduction Sanj K. Patel, Chief Executive Officer | | --- | | KPL-387 Development Program John F. Paolini, Chief Medical Officer | | ARCALYST® Commercial Execution Ross Moat, Chief Commercial Officer | | Fourth Quarter and Full Year 2024 Financial Results Mark Ragosa, Chief Financial Officer | | Closing Remarks Sanj K. Patel, Chief Executive Officer | | Q&A Session | 2 Forward Looking Statements This presentation (together with any other statements or information that we may m ...

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Q4 2024 Earnings Conference Call February 25, 2025 8:30 AM ET Company Participants Jonathan Kirshenbaum - Investor Relations Sanj Patel - Chairman and Chief Executive Officer John Paolini - Chief Medical Officer Ross Moat - Chief Commercial Officer Mark Ragosa - Chief Financial Officer Conference Call Participants Anupam Rama - JPMorgan Eva Fortea-Verdejo - Wells Fargo Paul Choi - Goldman Sachs Operator Good day and thank you for standing by. Welcome ...

Kiniksa Pharmaceuticals, Ltd. (KNSA) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to earnings of $0.04 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -100%. A quarter ago, it was expected that this company would post a loss of $0.01 per share when it actually produced a loss of $0.18, delivering a surprise of -1,700%.Over the last four quarters, the co ...

Revenue Performance - ARCALYST net product revenue for 2024 reached $416.4 million, reflecting a 79% year-over-year growth[1] - Kiniksa expects 2025 ARCALYST net product revenue to be between $560 million and $580 million[6] - There is substantial opportunity for Kiniksa to drive further ARCALYST revenue through its commercial strategy[2] Patient Engagement - Approximately 13% of the target population of 14,000 multiple-recurrence patients were actively on ARCALYST therapy by the end of 2024[5] - More than 2,850 prescribers have written ARCALYST prescriptions since its launch[5] - The average total duration of ARCALYST therapy in recurrent pericarditis was approximately 27 months as of the end of Q4 2024[5] Financial Position - Kiniksa had $243.6 million in cash, cash equivalents, and short-term investments as of December 31, 2024[11] - Kiniksa anticipates remaining cash flow positive on an annual basis[11] - Kiniksa's financial profile supports the pursuit of additional value-creating opportunities[2] Clinical Development - The company is advancing its clinical portfolio to bring new therapies to patients with unmet medical needs[2]

Core Insights - Kiniksa Pharmaceuticals reported strong sales growth for ARCALYST, achieving $417.0 million in net product revenue for the full year 2024, a 79% increase year-over-year [2][10] - The company expects ARCALYST net product revenue to reach between $560 million and $580 million in 2025 [2][10] - Kiniksa plans to discontinue the development of abiprubart in Sjögren's Disease and focus on cardiovascular indications [2][7] Financial Performance - Total revenue for Q4 2024 was $122.5 million, compared to $83.4 million in Q4 2023 [10][25] - Full year 2024 total revenue was $423.2 million, up from $270.3 million in 2023 [10][25] - The net loss for Q4 2024 was $8.9 million, compared to a net income of $25.2 million in Q4 2023 [10][25] - For the full year 2024, the net loss was $43.2 million, compared to a net income of $14.1 million in 2023 [10][25] Product Development - Kiniksa is advancing KPL-387 for recurrent pericarditis, with a Phase 2/3 clinical trial expected to start in mid-2025 [2][8][10] - KPL-387 aims to provide a single monthly subcutaneous injection option for patients [2][7] - KPL-1161 is also being developed with a target profile of quarterly subcutaneous dosing [7][9] Market Position - Since the launch of ARCALYST, over 2,850 prescribers have written prescriptions for recurrent pericarditis [7] - As of Q4 2024, approximately 13% of the target 14,000 multiple-recurrence patients were actively on ARCALYST treatment [7]

Core Insights - Kiniksa Pharmaceuticals plans to initiate a Phase 2/3 clinical trial of KPL-387 for recurrent pericarditis in mid-2025, with Phase 2 data expected in the second half of 2026 [1][2][4] - KPL-387 is a monoclonal antibody targeting IL-1R1, which may allow for monthly subcutaneous dosing, enhancing treatment options for patients [2][4][8] - The company will discontinue the development of abiprubart for Sjögren's Disease and is exploring strategic alternatives for this asset [1][4][13] Company Strategy - Kiniksa focuses on developing therapies for diseases with unmet needs, particularly in cardiovascular indications [1][4] - The company has successfully commercialized ARCALYST, generating over $800 million in product revenue since its launch in 2021, and has become cash flow positive annually [2][4] - Kiniksa aims to increase its market penetration in recurrent pericarditis with ARCALYST while advancing KPL-387 [2][4] Product Development - KPL-387 is currently undergoing a Phase 1 clinical trial, with topline data supporting the potential for monthly subcutaneous dosing [4][8] - Kiniksa is also advancing KPL-1161, another monoclonal antibody with a target profile of quarterly subcutaneous dosing [4][9] - The company has engaged with the FDA regarding the development of KPL-387 and plans to initiate further clinical trials [2][4][13]

Core Viewpoint - Kiniksa Pharmaceuticals International, plc will host a conference call on February 25, 2025, to discuss its fourth quarter and full year 2024 financial results and recent portfolio execution [1]. Group 1: Conference Call Details - The conference call is scheduled for 8:30 a.m. Eastern Time on February 25, 2025 [1]. - A live webcast will be available on the company's website, and participants can register for telephone access [2]. - A replay of the event will be accessible on Kiniksa's website approximately 48 hours after the event [2]. Group 2: Company Overview - Kiniksa is a biopharmaceutical company focused on developing novel therapies for debilitating diseases, particularly in cardiovascular indications [3]. - The company's portfolio is based on strong biologic rationale or validated mechanisms, offering potential for differentiation in the market [3].

Core Viewpoint - Kiniksa Pharmaceuticals International, plc will host a conference call on February 25, 2025, to discuss its fourth quarter and full year 2024 financial results and recent portfolio execution [1]. Group 1: Conference Call Details - The conference call is scheduled for 8:30 a.m. Eastern Time on February 25, 2025 [1]. - A live webcast will be available on the company's website, and participants can register for telephone access [2]. - A replay of the event will be accessible on Kiniksa's website within approximately 48 hours after the event [2]. Group 2: Company Overview - Kiniksa is a biopharmaceutical company focused on developing novel therapies for debilitating diseases, particularly in cardiovascular indications [3]. - The company's portfolio is based on strong biologic rationale or validated mechanisms, offering potential for differentiation in the market [3].

– ARCALYST® (rilonacept) 2024 net product revenue of $416.4 million (unaudited), representing ~79% year-over-year growth –– ARCALYST 2025 net product revenue expected to be $560 - $580 million –– Kiniksa expects to remain cash flow positive on an annual basis – LONDON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular a ...

Core Insights - Kiniksa Pharmaceuticals reported a preliminary unaudited net product revenue of $416.4 million for ARCALYST in 2024, reflecting approximately 79% year-over-year growth [1][2][6] - The company anticipates ARCALYST net product revenue for 2025 to be between $560 million and $580 million [1][6] - Kiniksa expects to maintain a cash flow positive status on an annual basis [1][6] Commercial Performance - As of the end of 2024, around 13% of the target population for recurrent pericarditis was on ARCALYST therapy, contributing to the revenue growth [2][6] - Since the launch of ARCALYST, over 2,850 prescribers have written prescriptions for the drug [6] - The average duration of ARCALYST therapy in recurrent pericarditis patients was approximately 27 months by the end of Q4 2024 [6] Corporate Update - Kiniksa's leadership, including Chairman and CEO Sanj K. Patel, presented at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025 [4] - The company is focused on advancing its clinical portfolio to address unmet medical needs [2][5] Product Information - ARCALYST is a recombinant dimeric fusion protein that inhibits interleukin-1 alpha and beta signaling, approved for treating recurrent pericarditis and other conditions [6][7] - The drug received Orphan Drug Exclusivity from the FDA for recurrent pericarditis in 2021 and Orphan Drug Designation from the European Commission for idiopathic pericarditis [7]